AUTHORS
Dai Chihara, MD, PhD, Ruitao Lin, PhD2, Ayushi Chauhan, MD3, Amanda Mason, RN4, Karmila Murphy, NP-C5, Lauren Johnson6, Jared Henderson, PhD7, Chijioke C Nze, MD, MPH8, Mark P Hamilton, MD9, Anath Christopher Lionel, MD, PhD10, Swaminathan P. Iyer, MD11, Sattva S Neelapu Sr, MD12, Christopher R. Flowers Jr, MD, MS13, Jason Westin, MD, MS, FACP, FASCO14, Loretta Nastoupil, MD15, Michael Green, PhD16
AFFILIATIONS
1 MD Anderson Cancer Center, Houston, Texas, United States
2 MD Anderson Cancer Center, Houston, Texas, United States
3 MD Anderson Cancer Center, Houston, Texas, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 MD Anderson Cancer Center, Houston, Texas, United States
6 MD Anderson Cancer Center, Houston, Texas, United States
7 MD Anderson Cancer Center, Houston, Texas, United States
8 MD Anderson Cancer Center, Houston, Texas, United States
9 MD Anderson Cancer Center, Houston, Texas, United States
10 MD Anderson Cancer Center, Houston, Texas, United States
11 MD Anderson Cancer Center, Houston, Texas, United States
12 MD Anderson Cancer Center, Houston, Texas, United States
13 MD Anderson Cancer Center, Houston, Texas, United States
14 MD Anderson Cancer Center, Houston, Texas, United States
15 MD Anderson Cancer Center, Houston, Texas, United States
16 MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: The treatment landscape of follicular lymphoma (FL) is rapidly evolving. Although outcomes have improved substantially with chemoimmunotherapy, lymphoma and treatment-related complications remain major causes of mortality, highlighting the need for effective, well-tolerated frontline therapies. As bispecific antibodies move into earlier treatment lines for relapsed/refractory FL, there is an increasing need for chemotherapy-free, T-cell sparing frontline treatment strategies. We hypothesized that time-limited treatment with obinutuzumab and golcadomide (G2) would achieve a high and durable complete response (CR) rate.
Methods: This is an open-label, single-arm phase 2 trial conducted at MD Anderson Cancer Center (NCT06108232). Eligible patients (pts) had histologically confirmed grade 1-3A FL and high tumor burden by GELF criteria. Pts received obinutuzumab 1,000 mg intravenously on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Golcadomide was administered on days 1-14 of each 28-day cycle. Following completion of the safety lead-in at 0.2 mg, the golcadomide dose was escalated to 0.4 mg for subsequent patients. Pts achieving CR after six cycles discontinued treatment without maintenance, whereas those with PR continued G2 through 12 cycles. The primary endpoint was CR rate after 6 cycles. An optional on-treatment biopsy was performed on cycle 2, day 1.
Results: The initially planned cohort of 33 patients completed enrollment, and all patients were evaluable for the primary endpoint. Three pts received golcadomide 0.2 mg in the safety lead-in cohort, and the remaining 30 patients received golcadomide 0.4 mg. The median age was 62 years (range, 42-74), and 94% of patients had advanced-stage disease. FLIPI risk was low, intermediate, and high in 12%, 42%, and 45% of patients, respectively; corresponding FLIPI24 risk were 12%, 67%, and 21%, respectively. All pts completed 6 cycles of treatment. The CR rate after 6 cycles was 94% (95% CI, 80-99%). Two pts with a PR after 6 cycles continued G2 through 12 cycles. Both pts subsequently converted to CR after 12 cycles, resulting in an end-of-treatment CR rate of 100%. One patient who achieved CR after six cycles subsequently experienced early disease progression associated with MYC translocation and transformation to double-hit lymphoma. With a median follow-up of 10 months (range, 5-28), the 1-year progression-free survival and overall survival estimates were 96% (95% CI, 76-99%) and 100%, respectively. The most common grade ≥3 adverse event was neutrophil count decreased (67%). Grade ≥3 nonhematologic adverse events were uncommon and included alanine aminotransferase (ALT) elevation (9%) and lung infection (9%); all other grade ≥3 nonhematologic adverse events occurred in one patient each (3%). The most common non-hematologic adverse events were constipation (58%), maculopapular rash (55%), cough (55%), and fatigue (42%), all of which were exclusively grade 1-2. Infection-related adverse events were generally infrequent and predominantly low grade, with no febrile neutropenia observed. Golcadomide dose reductions occurred in five patients because of persistent neutropenia despite G-CSF support (n=3), recurrent grade 3 liver enzyme elevation (n=1), and viral pneumonia (n=1).
Conclusion: Time-limited G2 demonstrated high efficacy with excellent tolerability in previously untreated high tumor burden FL, achieving a 94% CR rate after six cycles and 100% CR at completion of therapy. These findings support further evaluation of this chemotherapy-free, fixed-duration, maintenance-free regimen, and the study has expanded into an ongoing multicenter trial.
DISCLOSURES
Dai Chihara, MD, PhD: Chugai - Honoraria; Lyell - Research Funding; BMS - Research Funding; Genentech - Research Funding; Treeline - Research Funding; Genmab - Research Funding; Ono - Research Funding; REGENERON - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Miltenyi Biomedicine - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony)